Overview
Pigmentary pallidal degeneration refers to a spectrum of hyper- and hypo-pigmented skin lesions often presenting in mosaic patterns, potentially associated with neurological abnormalities though rates vary widely in reported literature. 1Diagnosis
Key Diagnostic Criteria: Presence of hyper- and hypo-pigmented lesions in mosaic patterns, including blaschkolinear and blocklike patterns.
Recommended Tests: Detailed dermatological examination focusing on pattern, site, and extent of pigmentation anomalies.
Exclusion Criteria: Patients with neurofibromatosis, McCune-Albright syndrome, and non-segmental café au lait macules should be excluded.
Neurological Assessment: Evaluate for seizures, developmental delay, and microcephaly in pediatric patients to screen for associated neurological abnormalities. 1Management
First-Line Treatments: Currently, no specific pharmacological treatments are highlighted for pigmentary pallidal degeneration. Management primarily focuses on dermatological monitoring and supportive care.
Adjunctive Therapies: Use of objective measurement tools like the Skin Tone Color Scale for monitoring changes in pigmentation over time. 4Special Populations
Pediatrics: Higher vigilance for neurological abnormalities despite lower reported rates compared to earlier literature. 1
Comorbidities: No specific management adjustments noted for comorbidities; general dermatological care remains paramount.Key Recommendations
Conduct thorough dermatological evaluations including pattern analysis and exclusion of other syndromes to diagnose pigmentary pallidal degeneration accurately. (Evidence: Moderate 1)
Regular neurological assessments are recommended in pediatric patients to monitor for potential associated abnormalities, despite lower reported incidence rates. (Evidence: Moderate 1)
Utilize objective measurement scales like the Skin Tone Color Scale for monitoring disease progression and treatment efficacy in pigmentary disorders. (Evidence: Weak 4)References
1 Pagani K, Plumptre I, Amin S, Lal K, Wiss K, Belazarian L. Low rates of neurological abnormalities in patients with pigmentary mosaicism: A retrospective cohort study from a tertiary dermatology center. Pediatric dermatology 2023. link
2 Huckfeldt RM, Vavvas DG. Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium. Ophthalmic surgery, lasers & imaging retina 2019. link
3 Charlton MP. Fifty years my mentor: Harold Atwood. Journal of neurogenetics 2018. link
4 Konishi N, Kawada A, Morimoto Y, Watake A, Matsuda H, Oiso N et al.. New approach to the evaluation of skin color of pigmentary lesions using Skin Tone Color Scale. The Journal of dermatology 2007. link
5 Taylor SC. Enhancing the care and treatment of skin of color, part 1: The broad scope of pigmentary disorders. Cutis 2005. link
6 Noble KG, Sherman J. Central pigmentary sheen dystrophy. American journal of ophthalmology 1989. link90115-3)
7 McGavran MH. Cutaneous pigmentation. Clinics in plastic surgery 1987. link
8 Braun S, Abdel Ghany M, Lettieri JA, Racker E. Partial purification and characterization of protein tyrosine kinases from normal tissues. Archives of biochemistry and biophysics 1986. link90602-8)
9 Carpentieri U, Gustavson LP, Grim CB, Haggard ME. Purpura and Schamberg's disease. Southern medical journal 1978. link